PMID- 20026821 OWN - NLM STAT- MEDLINE DA - 20091222 DCOM- 20100111 IS - 1538-361X (Electronic) IS - 1538-361X (Linking) VI - 135 IP - 12 DP - 2009 Dec TI - Transoral resection for squamous cell carcinoma of the base of the tongue. PG - 1231-8 AB - OBJECTIVE: To review the oncologic and functional outcomes of patients with squamous cell carcinoma of the base of the tongue who underwent transoral tumor resection and neck dissection with or without postoperative adjuvant therapy. DESIGN: Retrospective medical record review. SETTING: Tertiary referral center. PATIENTS: All patients undergoing transoral resection of squamous cell carcinoma on the base of the tongue as part of their primary treatment from January 1, 1996, through January 31, 2005. MAIN OUTCOME MEASURES: We analyzed overall survival, disease-specific survival, local control, and locoregional control rates using the Kaplan-Meier method. Speech and swallowing function and treatment-related morbidity were also analyzed. RESULTS: A total of 20 patients underwent transoral resection. Four patients had surgery only, 12 had surgery and radiotherapy, and 4 had surgery and chemoradiotherapy. One patient had stage II disease, 3 had stage III disease, and 16 had stage IVA disease. The Kaplan-Meier overall survival rate was 90.0%, and the disease-specific survival rate was 94.7% at 2 years, with a mean follow-up of 3.7 years. Median hospital stay was 4.7 days. Patients who received a tracheostomy underwent decannulation with a median tracheostomy time of 5.5 days. Seven of 9 patients who received a percutaneous endoscopic gastrostomy tube had it removed. Three patients developed local recurrence, there were no regional recurrences, and 2 patients developed distant metastasis. CONCLUSIONS: Transoral resection of squamous cell carcinoma of the base of the tongue with postoperative adjuvant therapy provided excellent local and regional control and minimized morbidity. Transoral resection is a reasonable treatment option for patients with oropharyngeal squamous cell carcinoma, resulting in very low overall loss of organ function in properly selected patients. AD - Department of Otorhinolaryngology, Mayo Clinic, 200 First Street SW, Rochester, MN 55905, USA. FAU - Henstrom, Douglas K AU - Henstrom DK FAU - Moore, Eric J AU - Moore EJ FAU - Olsen, Kerry D AU - Olsen KD FAU - Kasperbauer, Jan L AU - Kasperbauer JL FAU - McGree, Michaela E AU - McGree ME LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Arch Otolaryngol Head Neck Surg JT - Archives of otolaryngology--head & neck surgery JID - 8603209 SB - AIM SB - IM MH - Adult MH - Aged MH - Carcinoma, Squamous Cell/mortality/pathology/*surgery MH - Chemotherapy, Adjuvant MH - Enteral Nutrition MH - Female MH - Follow-Up Studies MH - Humans MH - Length of Stay MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local MH - Neoplasm Staging MH - Postoperative Complications MH - Radiotherapy, Adjuvant MH - Retrospective Studies MH - Survival Rate MH - Tongue Neoplasms/mortality/pathology/*surgery EDAT- 2009/12/23 06:00 MHDA- 2010/01/12 06:00 CRDT- 2009/12/23 06:00 AID - 135/12/1231 [pii] AID - 10.1001/archoto.2009.177 [doi] PST - ppublish SO - Arch Otolaryngol Head Neck Surg. 2009 Dec;135(12):1231-8. PMID- 19892663 OWN - NLM STAT- MEDLINE DA - 20091106 DCOM- 20100112 IS - 1940-6215 (Electronic) VI - 2 IP - 11 DP - 2009 Nov TI - Phase II randomized, placebo-controlled trial of green tea extract in patients with high-risk oral premalignant lesions. PG - 931-41 AB - Epidemiologic and preclinical data support the oral cancer prevention potential of green tea extract (GTE). We randomly assigned patients with high-risk oral premalignant lesions (OPL) to receive GTE at 500, 750, or 1,000 mg/m(2) or placebo thrice daily for 12 weeks, evaluating biomarkers in baseline and 12-week biopsies. The OPL clinical response rate was higher in all GTE arms (n = 28; 50%) versus placebo (n = 11; 18.2%; P = 0.09) but did not reach statistical significance. However, the two higher-dose GTE arms [58.8% (750 and 1,000 mg/m(2)), 36.4% (500 mg/m(2)), and 18.2% (placebo); P = 0.03] had higher responses, suggesting a dose-response effect. GTE treatment also improved histology (21.4% versus 9.1%; P = 0.65), although not statistically significant. GTE was well tolerated, although higher doses increased insomnia/nervousness but produced no grade 4 toxicity. Higher mean baseline stromal vascular endothelial growth factor (VEGF) correlated with a clinical (P = 0.04) but not histologic response. Baseline scores of other biomarkers (epithelial VEGF, p53, Ki-67, cyclin D1, and p16 promoter methylation) were not associated with a response or survival. Baseline p16 promoter methylation (n = 5) was associated with a shorter cancer-free survival. Stromal VEGF and cyclin D1 expression were downregulated in clinically responsive GTE patients and upregulated in nonresponsive patients at 12 weeks (versus at baseline). An extended (median, 27.5 months) follow-up showed a median time to oral cancer of 46.4 months. GTE may suppress OPLs, in part through reducing angiogenic stimulus (stromal VEGF). Higher doses of GTE may improve short-term (12-week) OPL outcome. The present results support longer-term clinical testing of GTE for oral cancer prevention. AD - Department of Thoracic/Head and Neck Medical Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA. FAU - Tsao, Anne S AU - Tsao AS FAU - Liu, Diane AU - Liu D FAU - Martin, Jack AU - Martin J FAU - Tang, Xi-ming AU - Tang XM FAU - Lee, J Jack AU - Lee JJ FAU - El-Naggar, Adel K AU - El-Naggar AK FAU - Wistuba, Ignacio AU - Wistuba I FAU - Culotta, Kirk S AU - Culotta KS FAU - Mao, Li AU - Mao L FAU - Gillenwater, Ann AU - Gillenwater A FAU - Sagesaka, Yuko M AU - Sagesaka YM FAU - Hong, Waun K AU - Hong WK FAU - Papadimitrakopoulou, Vassiliki AU - Papadimitrakopoulou V LA - eng PT - Clinical Trial, Phase II PT - Comparative Study PT - Journal Article PT - Randomized Controlled Trial PT - Research Support, Non-U.S. Gov't PL - United States TA - Cancer Prev Res (Phila Pa) JT - Cancer prevention research (Philadelphia, Pa.) JID - 101479409 RN - 0 (Placebos) RN - 0 (Plant Extracts) RN - 0 (RNA, Messenger) RN - 0 (Tea) RN - 0 (Vascular Endothelial Growth Factor A) SB - IM CIN - Cancer Prev Res (Phila Pa). 2009 Nov;2(11):919-21. PMID: 19892661 MH - Administration, Oral MH - Adolescent MH - Adult MH - Aged MH - Dose-Response Relationship, Drug MH - Female MH - Humans MH - Male MH - Middle Aged MH - Mouth Neoplasms/*prevention & control MH - *Phytotherapy MH - Placebos MH - Plant Extracts/pharmacokinetics/*therapeutic use MH - Precancerous Conditions/*prevention & control MH - RNA, Messenger/genetics/metabolism MH - Reverse Transcriptase Polymerase Chain Reaction MH - *Tea MH - Tissue Distribution MH - Treatment Outcome MH - Vascular Endothelial Growth Factor A/genetics/metabolism MH - Young Adult EDAT- 2009/11/07 06:00 MHDA- 2010/01/13 06:00 CRDT- 2009/11/07 06:00 AID - 2/11/931 [pii] AID - 10.1158/1940-6207.CAPR-09-0121 [doi] PST - ppublish SO - Cancer Prev Res (Phila Pa). 2009 Nov;2(11):931-41. PMID- 19892661 OWN - NLM STAT- MEDLINE DA - 20091106 DCOM- 20100112 IS - 1940-6215 (Electronic) VI - 2 IP - 11 DP - 2009 Nov TI - Oral cancer prevention advances with a translational trial of green tea. PG - 919-21 AB - This perspective on Tsao et al. (beginning on p. 931 in this issue of the journal) discusses green tea extract, which was shown for the first time to have dose-dependent effects in a clinical chemopreventive setting (oral premalignant lesions). This translational trial provides important data on angiogenesis and other biomarkers on which to base future clinical research, which should include trials of green tea extract or polyphenols combined with other natural or synthetic compounds to enhance chemopreventive effects. AD - Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, Georgia 30322, USA. dmshin@emory.edu FAU - Shin, Dong M AU - Shin DM LA - eng PT - Comment PT - Journal Article PL - United States TA - Cancer Prev Res (Phila Pa) JT - Cancer prevention research (Philadelphia, Pa.) JID - 101479409 RN - 0 (Plant Extracts) RN - 0 (Tea) SB - IM CON - Cancer Prev Res (Phila Pa). 2009 Nov;2(11):931-41. PMID: 19892663 MH - Humans MH - Mouth Neoplasms/*prevention & control MH - *Phytotherapy MH - Plant Extracts/*therapeutic use MH - Precancerous Conditions/*prevention & control MH - *Tea MH - Treatment Outcome EDAT- 2009/11/07 06:00 MHDA- 2010/01/13 06:00 CRDT- 2009/11/07 06:00 AID - 2/11/919 [pii] AID - 10.1158/1940-6207.CAPR-09-0207 [doi] PST - ppublish SO - Cancer Prev Res (Phila Pa). 2009 Nov;2(11):919-21. PMID- 19856305 OWN - NLM STAT- MEDLINE DA - 20091224 DCOM- 20100111 IS - 1531-4995 (Electronic) IS - 1531-4995 (Linking) VI - 120 IP - 1 DP - 2010 Jan TI - Chemoradiation for patients with advanced oral cavity cancer. PG - 93-9 AB - OBJECTIVES/HYPOTHESIS: Patients with advanced oral cavity cancer (OCC) typically have not been enrolled in clinical trials utilizing contemporary multimodality strategies. There exist dogmatic expectations of inferior outcome in OCC patients secondary to ineffectiveness of treatment and unacceptable toxicity. The purpose of this study was to analyze survival, swallowing function, and incidence of osteoradionecrosis (ORN) of patients with stage III/IV OCC who have undergone primary concomitant chemoradiotherapy (CRT). METHODS: All advanced OCC patients who were enrolled in University of Chicago concomitant CRT protocols from 1994 to 2008 were reviewed. One hundred eleven newly diagnosed advanced OCC patients were evaluated. We performed a subset analysis of 27 additional advanced OCC patients who underwent surgery followed by postoperative CRT. Swallowing function was assessed via oropharyngeal motility study, and a Swallowing Performance Status Scale score was assigned. Presence of clinically significant ORN was documented. RESULTS: Median follow-up was 3.25 years. Five-year overall and progression-free survival was 66.9% and 65.9%, respectively. There was no difference in overall or progression-free survival when the surgery-first group was compared with the primary CRT group (P = .88 and P = .86 respectively). Function, without gastric tube requirement, was excellent, with 92.2% of patients able to maintain weight via oral route. Incidence of ORN was 18.4%, occurring in nine of 49 patients evaluated. CONCLUSIONS: Our data support the use of primary CRT as a viable treatment option for patients with advanced OCC. Survival is high, and overall function for the majority of patients is satisfactory. Patients with T4 oral tongue cancer may be spared total glossectomy. The incidence of ORN may be considered acceptable, in light of the benefits of enduring life and function. AD - Section of Otolaryngology/Head and Neck Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA. kstenson@surgery.bsd.uchicago.edu FAU - Stenson, Kerstin M AU - Stenson KM FAU - Kunnavakkam, Rangesh AU - Kunnavakkam R FAU - Cohen, Ezra E W AU - Cohen EE FAU - Portugal, Louis D AU - Portugal LD FAU - Blair, Elizabeth AU - Blair E FAU - Haraf, Daniel J AU - Haraf DJ FAU - Salama, Joseph AU - Salama J FAU - Vokes, Everett E AU - Vokes EE LA - eng PT - Comparative Study PT - Journal Article PL - United States TA - Laryngoscope JT - The Laryngoscope JID - 8607378 SB - IM MH - Combined Modality Therapy MH - Deglutition/physiology MH - Disease-Free Survival MH - Female MH - Follow-Up Studies MH - Humans MH - Male MH - Middle Aged MH - Mouth Neoplasms/drug therapy/mortality/radiotherapy/surgery/*therapy MH - Osteoradionecrosis/etiology MH - Tongue Neoplasms/therapy EDAT- 2009/10/27 06:00 MHDA- 2010/01/12 06:00 CRDT- 2009/10/27 06:00 AID - 10.1002/lary.20716 [doi] PST - ppublish SO - Laryngoscope. 2010 Jan;120(1):93-9. PMID- 19795174 OWN - NLM STAT- MEDLINE DA - 20091027 DCOM- 20100119 IS - 1534-4681 (Electronic) IS - 1534-4681 (Linking) VI - 16 IP - 11 DP - 2009 Nov TI - Joint practice guidelines for radionuclide lymphoscintigraphy for sentinel node localization in oral/oropharyngeal squamous cell carcinoma. PG - 3190-210 AB - Involvement of the cervical lymph nodes is the most important prognostic factor for patients with oral/oropharyngeal squamous cell carcinoma (OSCC), and the decision of whether to electively treat patients with clinically negative necks remains a controversial topic. Sentinel node biopsy (SNB) provides a minimally invasive method for determining the disease status of the cervical node basin, without the need for a formal neck dissection. This technique potentially improves the accuracy of histologic nodal staging and avoids overtreating three-quarters of this patient population, minimizing associated morbidity. The technique has been validated for patients with OSCC, and larger-scale studies are in progress to determine its exact role in the management of this patient population. This document is designed to outline the current best practice guidelines for the provision of SNB in patients with early-stage OSCC, and to provide a framework for the currently evolving recommendations for its use. Preparation of this guideline was carried out by a multidisciplinary surgical/nuclear medicine/pathology expert panel under the joint auspices of the European Association of Nuclear Medicine (EANM) Oncology Committee and the Sentinel European Node Trial (SENT) Committee. AD - Department of Plastic Surgery, University of Chicago Medical Center, Chicago, USA. lee_alkureishi@hotmail.com FAU - Alkureishi, L W T AU - Alkureishi LW FAU - Burak, Z AU - Burak Z FAU - Alvarez, J A AU - Alvarez JA FAU - Ballinger, J AU - Ballinger J FAU - Bilde, A AU - Bilde A FAU - Britten, A J AU - Britten AJ FAU - Calabrese, L AU - Calabrese L FAU - Chiesa, C AU - Chiesa C FAU - Chiti, A AU - Chiti A FAU - de Bree, R AU - de Bree R FAU - Gray, H W AU - Gray HW FAU - Hunter, K AU - Hunter K FAU - Kovacs, A F AU - Kovacs AF FAU - Lassmann, M AU - Lassmann M FAU - Leemans, C R AU - Leemans CR FAU - Mamelle, G AU - Mamelle G FAU - McGurk, M AU - McGurk M FAU - Mortensen, J AU - Mortensen J FAU - Poli, T AU - Poli T FAU - Shoaib, T AU - Shoaib T FAU - Sloan, P AU - Sloan P FAU - Sorensen, J A AU - Sorensen JA FAU - Stoeckli, S J AU - Stoeckli SJ FAU - Thomsen, J B AU - Thomsen JB FAU - Trifiro, G AU - Trifiro G FAU - Werner, J AU - Werner J FAU - Ross, G L AU - Ross GL CN - European Association of Nuclear Medicine Oncology Committee CN - European Sentinel Node Biopsy Trial Committee LA - eng PT - Journal Article PT - Practice Guideline PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Carcinoma, Squamous Cell/*radionuclide imaging/secondary/surgery MH - Humans MH - Lymph Nodes/pathology/*radionuclide imaging/surgery MH - Mouth Neoplasms/pathology/*radionuclide imaging/surgery MH - Oropharyngeal Neoplasms/pathology/*radionuclide imaging/surgery MH - Prognosis MH - Sentinel Lymph Node Biopsy PMC - PMC2766455 OID - NLM: PMC2766455 EDAT- 2009/10/02 06:00 MHDA- 2010/01/20 06:00 CRDT- 2009/10/02 06:00 PHST- 2009/07/23 [received] PHST- 2009/10/01 [aheadofprint] AID - 10.1245/s10434-009-0726-8 [doi] PST - ppublish SO - Ann Surg Oncol. 2009 Nov;16(11):3190-210. PMID- 19721098 OWN - NLM STAT- MEDLINE DA - 20090917 DCOM- 20100126 IS - 1545-1097 (Print) IS - 1545-1097 (Linking) VI - 8 IP - 5 DP - 2009 Sep-Oct TI - A retrospective analysis of AIDS-associated Kaposi's sarcoma in patients with undetectable HIV viral loads and CD4 counts greater than 300 cells/mm(3). PG - 279-85 AB - OBJECTIVE: To compare the clinical course of patients with AIDS-related Kaposi's sarcoma (KS) with CD4 counts >300 cells/mm(3) and undetectable HIV viral loads (VLs) to patients with AIDS-KS with lesser CD4 counts and detectable HIV VLs. METHODS: We retrospectively analyzed a cohort of 91 patients with AIDS-KS in a multispeciality clinic. We used chi(2) and Student t tests to analyze intragroup differences; survival was determined by Kaplan-Meier analysis. RESULTS: Twenty (22%) of the 91 patients had newly diagnosed, persistent or progressive KS despite CD4 counts >300 cells/mm(3) and undetectable HIV VLs. Age, gender, ethnicity, mode and duration of HIV acquisition, type of antiretroviral therapy (ART), and KS therapy did not differ significantly (P < or = .005) between this group and the remaining 71 patients. Although tumor stage and response to KS therapy were similar, there was a significantly greater risk of death among the patients with CD4 counts <300 cells/mm(3) and detectable HIV VLs (P = .048). CONCLUSIONS: In the highly active antiretroviral (HAART) era, a substantial proportion of patients with KS had undetectable HIV VLs and CD4 counts greater than the level typically associated with opportunistic diseases. They required systemic therapy to control their KS but were significantly less likely to die and demonstrated a trend toward better 15-year survival than patients having KS with lesser CD4 counts and detectable HIV VLs. AD - Division of Internal Medicine, Spokane Medical Centers, Spokane, WA, USA. FAU - Mani, Deepthi AU - Mani D FAU - Neil, Nancy AU - Neil N FAU - Israel, Rebecca AU - Israel R FAU - Aboulafia, David M AU - Aboulafia DM LA - eng PT - Journal Article PT - Research Support, N.I.H., Extramural PT - Research Support, Non-U.S. Gov't DEP - 20090831 PL - United States TA - J Int Assoc Physicians AIDS Care (Chic Ill) JT - Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) JID - 101185740 SB - IM MH - Adult MH - Aged MH - Antiretroviral Therapy, Highly Active MH - *CD4 Lymphocyte Count MH - Cohort Studies MH - Female MH - HIV Infections/*blood/drug therapy/epidemiology MH - Humans MH - Kaplan-Meiers Estimate MH - Lymph Nodes/pathology MH - Male MH - Middle Aged MH - Mouth Neoplasms/mortality/pathology/therapy MH - Retrospective Studies MH - Sarcoma, Kaposi/*mortality/pathology/therapy MH - Skin Neoplasms/mortality/pathology/therapy MH - *Viral Load EDAT- 2009/09/02 06:00 MHDA- 2010/01/27 06:00 CRDT- 2009/09/02 09:00 PHST- 2009/08/31 [aheadofprint] AID - 1545109709341852 [pii] AID - 10.1177/1545109709341852 [doi] PST - ppublish SO - J Int Assoc Physicians AIDS Care (Chic Ill). 2009 Sep-Oct;8(5):279-85. Epub 2009 Aug 31. PMID- 19671846 OWN - NLM STAT- MEDLINE DA - 20090814 DCOM- 20091229 IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 15 IP - 16 DP - 2009 Aug 15 TI - Methylation of p16 CpG island associated with malignant progression of oral epithelial dysplasia: a prospective cohort study. PG - 5178-83 AB - PURPOSE: Inactivation of p16 gene by CpG methylation is a frequent event in oral epithelial dysplasia. To investigate the predictive value of p16 methylation on malignant potential in oral epithelial dysplasia, we carried out the prospective cohort study. EXPERIMENTAL DESIGN: One hundred one patients with histologically confirmed mild or moderate oral epithelial dysplasia were included in the present cohort study. p16 Methylation status of the oral epithelial dysplasia lesions from 93 cases was obtained by methylation-specific PCR. Progression of the oral epithelial dysplasia lesions was examined in 78 cases histologically during a 45.8 months follow-up period. The association between p16 methylation and progression of oral epithelial dysplasia was analyzed. RESULTS: Of the 93 enrolled cases, 15 cases were lost during the follow-up because of changes of contact information, with a compliance of 83.9%. p16 Methylation was detectable in oral epithelial dysplasia lesions from 32 (41.0%) of 78 enrolled patients. Oral epithelial dysplasia-related squamous cell carcinomas were observed in 22 patients (28.2%) during the follow-up. Rate of progression to oral cancer in patients with the p16-methylated oral epithelial dysplasia was significantly higher than that with the p16-unmethylated oral epithelial dysplasia (43.8% versus 17.4%; adjusted odds ratio, 3.7; P = 0.013), especially for patients at the baseline age of > or = 60 years (adjusted odds ratio, 12.0; P = 0.003) and patients with moderate oral epithelial dysplasia (adjusted odds ratio, 15.6; P = 0.022). The overall sensitivity and specificity of prediction of malignant transformation of oral epithelial dysplasia by p16 methylation were 63.6% and 67.9%, respectively. CONCLUSION: p16 Methylation was correlated with malignant transformation of oral epithelial dysplasia and is a potential biomarker for prediction of prognosis of mild or moderate oral epithelial dysplasia. AD - Peking University School and Hospital of Stomatology, Beijing, China. FAU - Cao, Jie AU - Cao J FAU - Zhou, Jing AU - Zhou J FAU - Gao, Yan AU - Gao Y FAU - Gu, Liankun AU - Gu L FAU - Meng, Huanxin AU - Meng H FAU - Liu, Hongwei AU - Liu H FAU - Deng, Dajun AU - Deng D LA - eng PT - Evaluation Studies PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20090811 PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 SB - IM MH - Adult MH - Aged MH - Algorithms MH - Biopsy MH - Carcinoma, Squamous Cell/diagnosis/*genetics/pathology MH - Cohort Studies MH - *CpG Islands/physiology MH - DNA Methylation/*physiology MH - Disease Progression MH - Epithelial Cells/pathology MH - Female MH - Follow-Up Studies MH - *Genes, p16 MH - Humans MH - Male MH - Middle Aged MH - Mouth Mucosa/pathology MH - Mouth Neoplasms/diagnosis/*genetics/pathology MH - Precancerous Conditions/genetics/*pathology MH - Prognosis MH - Sensitivity and Specificity EDAT- 2009/08/13 09:00 MHDA- 2009/12/30 06:00 CRDT- 2009/08/13 09:00 PHST- 2009/08/11 [aheadofprint] AID - 1078-0432.CCR-09-0580 [pii] AID - 10.1158/1078-0432.CCR-09-0580 [doi] PST - ppublish SO - Clin Cancer Res. 2009 Aug 15;15(16):5178-83. Epub 2009 Aug 11. PMID- 19636629 OWN - NLM STAT- MEDLINE DA - 20091026 DCOM- 20100119 IS - 1534-4681 (Electronic) IS - 1534-4681 (Linking) VI - 16 IP - 11 DP - 2009 Nov TI - Is there an additional value of SPECT/CT over planar lymphoscintigraphy for sentinel node mapping in oral/oropharyngeal squamous cell carcinoma? PG - 3118-24 AB - BACKGROUND: Lymphatic mapping for sentinel node biopsy (SNB) has been shown to be crucial for detection of sentinel lymph nodes (SLN). Previous reports suggested a benefit of single photon emission computed tomography with CT (SPECT/CT) over dynamic planar lymphoscintigraphy (LS) alone. The aim was to assess whether there is an additional value of SPECT/CT over LS alone for lymphatic mapping of SLNs in oral/oropharyngeal SCC. METHODS: A consecutive cohort of 58 patients was evaluated using SNB with additional SPECT/CT to preoperative LS. RESULTS: In the entire cohort of 58 patients undergoing LS and SPECT/CT, hot spots could be revealed in all but 4 cases. The guidance of the handheld gamma probe was able to reveal 9 additional SLNs within 3 patients not detected by either modality. Lymphoscintigraphy showed full concordance with SPECT/CT in 81% of the cases. SPECT/CT was able to detect additional HS in 11 patients, in 1 case even with additional metastatic disease. The false negative rate for SNB was 6%, and the negative predictive value 98%. CONCLUSIONS: SPECT/CT has the potential to detect more SLNs, which might harbor occult disease, than LS alone. With regard to the excellent results achieved with LS and the intraoperative use of the gamma probe, SPECT/CT is not indispensable for successful SNB. Both imaging modalities have difficulties in detecting level I sentinel nodes close to the injection site. AD - Department of Otolaryngology, Head and Neck Surgery, University Hospital Zurich, Zurich, Switzerland. FAU - Haerle, Stephan K AU - Haerle SK FAU - Hany, Thomas F AU - Hany TF FAU - Strobel, Klaus AU - Strobel K FAU - Sidler, Daniel AU - Sidler D FAU - Stoeckli, Sandro J AU - Stoeckli SJ LA - eng PT - Journal Article DEP - 20090728 PL - United States TA - Ann Surg Oncol JT - Annals of surgical oncology JID - 9420840 SB - IM MH - Adult MH - Aged MH - Aged, 80 and over MH - Carcinoma, Squamous Cell/diagnosis/secondary/surgery MH - Cohort Studies MH - Female MH - Humans MH - Lymph Nodes/*radiography/*radionuclide imaging MH - Lymphatic Metastasis MH - Male MH - Middle Aged MH - Mouth Neoplasms/*diagnosis/surgery MH - Neoplasm Recurrence, Local/diagnosis/surgery MH - Neoplasm Staging MH - Oropharyngeal Neoplasms/*diagnosis/surgery MH - Prognosis MH - Prospective Studies MH - Sentinel Lymph Node Biopsy MH - Survival Rate MH - *Tomography, Emission-Computed, Single-Photon MH - *Tomography, X-Ray Computed MH - Treatment Outcome EDAT- 2009/07/29 09:00 MHDA- 2010/01/20 06:00 CRDT- 2009/07/29 09:00 PHST- 2008/12/04 [received] PHST- 2009/07/02 [accepted] PHST- 2009/07/01 [revised] PHST- 2009/07/28 [aheadofprint] AID - 10.1245/s10434-009-0632-0 [doi] PST - ppublish SO - Ann Surg Oncol. 2009 Nov;16(11):3118-24. Epub 2009 Jul 28. PMID- 19628944 OWN - NLM STAT- MEDLINE DA - 20090924 DCOM- 20100118 IS - 1421-9921 (Electronic) IS - 1421-9921 (Linking) VI - 43 IP - 3 DP - 2009 TI - Functional rehabilitation of mandibular continuity defects using autologous bone and dental implants - prognostic value of bone origin, radiation therapy and implant dimensions. PG - 269-75 AB - AIM: The aim of this retrospective study was to investigate prognostic parameters for the rehabilitation of mandibular continuity defects with free autologous bone and dental implants for patients after intraoral squamous cell carcinoma. METHODS: Following potential prognostic factors for implant survival were analyzed: bony bed (local bone versus augmented iliac crest bone), radiation dose (no radiation, <50 Gy, >or=50 Gy) and implant dimensions. Kaplan-Meier survival estimates of the inserted implants were performed. RESULTS: After 5 years, the cumulative survival rate of all investigated implants was 82.6%. Dental implantation into augmented bone resulted in a significantly lower survival rate (78.4%), compared to original local bone (92.8%). Modifications of implant dimensions as well as radiation therapy showed no significant impact on implant survival. CONCLUSION: For the investigated compromised collective, our results reveal a satisfactory long-term survival rate of dental implants even in augmented bone and underline the value of dental implantation for the functional rehabilitation of cancer patients. CI - Copyright 2009 S. Karger AG, Basel. AD - Department of Oral and Maxillofacial Surgery, Johannes Gutenberg University Mainz, Mainz, Germany. klein@mkg.klinik.uni-mainz.de FAU - Klein, M O AU - Klein MO FAU - Grotz, K A AU - Grotz KA FAU - Walter, C AU - Walter C FAU - Wegener, J AU - Wegener J FAU - Wagner, W AU - Wagner W FAU - Al-Nawas, B AU - Al-Nawas B LA - eng PT - Journal Article DEP - 20090723 PL - Switzerland TA - Eur Surg Res JT - European surgical research. Europaische chirurgische Forschung. Recherches chirurgicales europeennes JID - 0174752 SB - IM MH - *Bone Transplantation MH - Carcinoma, Squamous Cell/radiotherapy/rehabilitation/surgery MH - Dental Implantation/*statistics & numerical data MH - Dental Restoration Failure MH - Female MH - Humans MH - Kaplan-Meiers Estimate MH - Male MH - Mandible/radiation effects/*surgery MH - Middle Aged MH - Mouth Neoplasms/radiotherapy/rehabilitation/surgery MH - Retrospective Studies MH - Transplantation, Autologous EDAT- 2009/07/25 09:00 MHDA- 2010/01/19 06:00 CRDT- 2009/07/25 09:00 PHST- 2008/12/04 [received] PHST- 2009/05/05 [accepted] PHST- 2009/07/23 [aheadofprint] AID - 000229027 [pii] AID - 10.1159/000229027 [doi] PST - ppublish SO - Eur Surg Res. 2009;43(3):269-75. Epub 2009 Jul 23. PMID- 19609618 OWN - NLM STAT- MEDLINE DA - 20091026 DCOM- 20100119 IS - 1534-4681 (Electronic) IS - 1534-4681 (Linking) VI - 16 IP - 11 DP - 2009 Nov TI - Metabolic tumor volumes by [18F]-fluorodeoxyglucose PET/CT correlate with occult metastasis in oral squamous cell carcinoma of the tongue. PG - 3111-7 AB - BACKGROUND: To investigate the correlation between pretreatment metabolic tumor volume (MTV) as determined by [(18)F]-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) and occult metastasis (OM) in oral squamous cell carcinoma (OSCC) of the tongue. METHODS: Forty-three clinically node-negative (cN0) OSCC patients, diagnosed by preoperative workups (biopsy, physical examination, CT, and PET/CT) were enrolled. All patients had undergone primary tumor resections and elective neck dissections. MTVs were measured for tumors showing standardized uptake value (SUV) of >2.5 by an automated contouring program. Pretreatment variables (age, sex, clinical T stage, maximal SUV [SUV(max)] and MTV) and posttreatment variables (pathologic T stage, depth of invasion, lymphovascular invasion, pathologic tumor volume, and histological differentiation) were analyzed to identify their correlation with OM. RESULTS: Twelve (27.9%) of 43 patients were found to have OM in pathologic specimen of neck dissections. A cutoff of 6.0 ml for the MTV was determined to be the most discriminative value for predicting OM. By univariate analysis, the patients with an MTV of >6.0 ml had significantly higher number of occult metastases than those with an MTV of